fda warning letters compounded semaglutide 2025 september Sends to More Than 50 GLP-1 Compounders and Manufacturers There's lots going on this

doi: 10.1210/jcem.77.1.8325948

Delayed gastric emptying induced by GLP-1 receptor agonists carries important clinical implications that extend beyond the intended therapeutic effects

L., Gilchrist, R

In addition to weight reduction, GLP-1 agonists improve glycemic control in people with type 2 diabetes, making them a powerful tool for managing both weight and metabolic health

By two weeks after an injection, levels drop to about 25% of peak, which becomes too low to maintain consistent appetite suppression and weight loss effects

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE Obesity)